Iovance Biotherapeutics
IOVA
249 hedge funds and large institutions have $2.6B invested in Iovance Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 109 increasing their positions, 66 reducing their positions, and 39 closing their positions.
458% more call options, than puts
Call options by funds: $41.7M | Put options by funds: $7.48M
65% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 66
18% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 39
1% more funds holding
Funds holding: 246 → 249 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.16% less ownership
Funds ownership: 99.36% → 99.21% (-0.16%)
12% less capital invested
Capital invested by funds: $2.96B → $2.6B (-$366M)
Top Buyers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$35M |
| 2 |
PA
Perceptive Advisors
New York
|
+$32.1M |
| 3 |
Millennium Management
New York
|
+$31.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$27.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$26.4M |
Top Sellers
IOVA Hedge Fund Activity: Q1 2022 in Review
249 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2022, worth a combined $2.6B — down 12% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new IOVA positions and 39 closed out — a net gain of 7 holders — while 109 added to existing stakes and 66 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $35M. The largest seller was ARK Investment Management, cutting an estimated $64.4M.
- 249 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2022, up from 246 in Q4 2021.
- Funds reported $2.6B of Iovance Biotherapeutics stock for Q1 2022, down 12% quarter-over-quarter.
- 46 funds opened new Iovance Biotherapeutics positions in Q1 2022 and 39 closed out, a net change of +7 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2022 was Avidity Partners Management, an estimated $35M added.
- The largest Iovance Biotherapeutics seller in Q1 2022 was ARK Investment Management, an estimated $64.4M sold.
Based on aggregated 13F filings for Q1 2022.